What Are the Clinical Implications?
bleeding
BLEEDING
In patients at high bleeding risk who are meant to receive 1 month of dual antiplatelet therapy after percutaneous coronary intervention, the use of biodegradable-polymer sirolimus-eluting stents is a reasonable alternative to the use of durable-polymer zotarolimus-eluting stents at the time of intervention.More than one-third of patients treated with percutaneous coronary intervention (PCI) are considered to be at high bleeding risk and are frequently excluded from stent trials.Previous randomized controlled studies have shown better outcomes with drug-eluting stents than bare-metal stents in patients at high bleeding risk who were treated with 1 or 6 months of DAPT after PCI.We conducted a randomized trial to compare the safety and effectiveness of the biodegradable-polymer sirolimus-eluting stent with the durable-polymer zotarolimus-eluting stent in patients at high bleeding risk receiving 1 month of DAPT after PCI.